Abstract
The co-occurrence of BCR-ABL1 fusion and core-binding factor (CBF) rearrangements is uncommonly reported in AML. Although CBF rearrangements carry a favorable prognosis, the coexistence of BCR-ABL1 is associated with aggressive disease suggesting a potential advantage of high-intensity chemotherapy in association with tyrosine kinase inhibitors. Herein, we describe a refractory AML patient harboring BCR-ABL1 fusion and CBFB rearrangement that was successfully treated with a combination of venetoclax and hypomethylating agent.
Keywords:
Acute myeloid leukemia; BCR-ABL1; CBFB rearrangement; Hypometylating agents; Venetoclax.
© 2020 S. Karger AG, Basel.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Azacitidine / adverse effects
-
Azacitidine / therapeutic use*
-
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
-
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
-
Fusion Proteins, bcr-abl / genetics*
-
Hematologic Diseases / etiology
-
Humans
-
Karyotype
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Middle Aged
-
Oncogene Proteins, Fusion / genetics*
-
Remission Induction
-
Sulfonamides / adverse effects
-
Sulfonamides / therapeutic use*
Substances
-
Antineoplastic Agents
-
Bridged Bicyclo Compounds, Heterocyclic
-
CBFbeta-MYH11 fusion protein
-
Oncogene Proteins, Fusion
-
Sulfonamides
-
Fusion Proteins, bcr-abl
-
Azacitidine
-
venetoclax